v3.25.4
CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT - USD ($)
$ in Thousands
Total
Blue Owl Warrants
Hawthorn Agreement
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Blue Owl Warrants
Additional Paid-in Capital
Hawthorn Agreement
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023 0                  
Beginning balance at Dec. 31, 2023 $ 0                  
Ending balance (in shares) at Dec. 31, 2024 0                  
Ending balance at Dec. 31, 2024 $ 0     $ 0 $ 0          
Beginning balance (in shares) at Dec. 31, 2023           4,074,000        
Beginning balance at Dec. 31, 2023 (27,992)         $ 0 $ 94,544     $ (122,536)
Stockholders’ Deficit                    
Stock options exercised (in shares)           45,000        
Stock options exercised 211           211      
Vesting of restricted stock units (in shares)           163,000        
Repurchase of restricted stock for payroll tax withholding (in shares)           (47,000)        
Repurchases of restricted stock for payroll tax withholding (613)           (613)      
Stock-based compensation expense 5,759           5,759      
Issuance of shares due to litigation settlement (in shares)           212,000        
Issuance of shares due to litigation settlement 1,756           1,756      
Net income (loss) $ (25,915)                 (25,915)
Ending balance (in shares) at Dec. 31, 2024 4,446,540         4,447,000        
Ending balance at Dec. 31, 2024 $ (46,794)         $ 0 101,657     (148,451)
Mezzanine Equity                    
Issuance of Series A And B convertible preferred stock in connection with the Hawthorn Agreement (in shares)       35,000,000 30,000,000          
Issuance of Series A And B convertible preferred stock in connection with the Hawthorn Agreement       $ 11,308 $ 16,601          
Ending balance (in shares) at Dec. 31, 2025 65,000,000     35,000 30,000          
Ending balance at Dec. 31, 2025 $ 27,909     $ 11,308 $ 16,601          
Stockholders’ Deficit                    
Stock options exercised (in shares)           2,000        
Stock options exercised 8           8      
Vesting of restricted stock units (in shares)           192,000        
Repurchase of restricted stock for payroll tax withholding (in shares)           (59,000)        
Repurchases of restricted stock for payroll tax withholding (594)           (594)      
Stock-based compensation expense 3,693           3,693      
Repurchase of 2023 and 2025 Blue Owl Warrants (6,162)           (6,162)      
Repurchase of warrants   $ 3,934 $ 4,963         $ 3,934 $ 4,963  
Issuance of shares due to litigation settlement (in shares)           168,000        
Issuance of shares due to litigation settlement 1,504           1,504      
Net income (loss) $ 1,365                 1,365
Ending balance (in shares) at Dec. 31, 2025 4,750,258         4,750,000        
Ending balance at Dec. 31, 2025 $ (38,083)         $ 0 $ 109,003     $ (147,086)